|
Becton Dickinson & Company |
|
|
One Becton Drive
Franklin Lakes, NJ 07417 USA
phone:201-847-6800
fax:201-847-6475
|
|
| Symbol |
BDX |
| Exchange |
NASDAQ |
| Founded |
0 |
| Employees |
24780 |
|
|
| www.bd.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Manufactures and Markets Medical and Laboratory Supplies, Devices and Diagnostic Products |
|
| Management |
| Edward J. Ludwig, CEO; John R. Considine, CFO |
| |
|
|
|
|
|
|
|
| Keywords |
| diagnostic, devices, laboratory, lab, equipment |
|
|
|
| Description |
|
Becton, Dickinson and Company (BD) is a global medical technology company that is focused on improving drug therapy, enhancing the diagnosis of infectious diseases and advancing drug discovery. BD manufactures and markets its products via three segments: BD Medical, BD Diagnostics and BD Biosciences. |
|
| Products / Services |
BD's extensive product and service offerings include: allergy syringes, anesthesiology products, antibodies and reagents, arthritis relief products, biodefense products, blood / urine collection tools, catheters and IV maintenance equipment, cell culture products, cell sorters, cervical cytology technology, flow cytometers, diabetes care supplies, diagnostic tests, education center, elastic bandages and braces.
|
|
| Technology / Differentiation |
| BD built the first-ever manufacturing facility in the U.S. for the production of syringes and needles in 1906; the company is still heavily involved in developing and marketing its injection and infusion-based drug delivery systems. BD Diagnostics offers two operating units: Preanalytical Systems for sample collection and Diagnostic Systems for microbiology testing products and molecular assays. The company has developed proprietary technology for the following applications: medication delivery, blood collection, diagnostic testing, flow cytometry, infusion therapy, surgery, anesthesia delivery, ophthalmology, critical care, immunization, sharps disposal and medication management. |
|
| Market / Customers |
BD's target customers include healthcare institutions, life science researchers, clinical laboratories, industry and the general public. Its products and technologies present potential benefits for several billion-dollar healthcare and life science markets.
|
|
| Status |
| In July 2008, BD Diagnostics announced the CE marking of the BD GeneOhm Cdiff molecular assay for the rapid diagnosis of patients with Clostridium difficile infection (CDI). The company has also submitted this assay to the U.S. FDA for clearance. BD reported record quarterly revenues of $1.868 billion for the third fiscal quarter ended June 30, 2008, which represents an increase of 14.5 percent over the prior year period. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members